iShares U.S. Pharmaceuticals ETF $IHE Stock Sold by Insight Wealth Strategies LLC

Insight Wealth Strategies LLC reduced its holdings in shares of iShares U.S. Pharmaceuticals ETF (NYSEARCA:IHE) by 97.2% during the third quarter, HoldingsChannel.com reports. The fund owned 3,461 shares of the company’s stock after selling 119,181 shares during the quarter. Insight Wealth Strategies LLC’s holdings in iShares U.S. Pharmaceuticals ETF were worth $348,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently made changes to their positions in IHE. Cetera Investment Advisers boosted its holdings in shares of iShares U.S. Pharmaceuticals ETF by 675.4% in the 1st quarter. Cetera Investment Advisers now owns 109,471 shares of the company’s stock worth $9,489,000 after buying an additional 95,353 shares during the last quarter. Congress Asset Management Co. bought a new position in shares of iShares U.S. Pharmaceuticals ETF during the 3rd quarter valued at approximately $56,000. Tidal Investments LLC bought a new stake in shares of iShares U.S. Pharmaceuticals ETF in the 2nd quarter worth approximately $3,716,000. Lee Johnson Capital Management LLC bought a new stake in shares of iShares U.S. Pharmaceuticals ETF in the 1st quarter worth approximately $1,603,000. Finally, Bank of America Corp DE lifted its stake in iShares U.S. Pharmaceuticals ETF by 2.8% in the first quarter. Bank of America Corp DE now owns 456,606 shares of the company’s stock valued at $39,579,000 after purchasing an additional 12,565 shares during the last quarter.

iShares U.S. Pharmaceuticals ETF Stock Performance

NYSEARCA IHE traded up $1.32 on Friday, hitting $100.18. 109,617 shares of the stock traded hands, compared to its average volume of 164,446. The business’s fifty day moving average is $102.73 and its two-hundred day moving average is $96.04. iShares U.S. Pharmaceuticals ETF has a 12 month low of $72.94 and a 12 month high of $108.66. The firm has a market capitalization of $1.63 billion, a price-to-earnings ratio of 17.75 and a beta of 0.47.

iShares U.S. Pharmaceuticals ETF Company Profile

iShares U.S. Pharmaceuticals ETF, formerly iShares Dow Jones U.S. Pharmaceuticals Index Fund (the Fund), is an exchange traded fund. The Fund seeks investment results that correspond generally to the price and yield performance of the Dow Jones U.S. Select Pharmaceuticals Index (the Index). The Index measures the performance of the pharmaceuticals sector of the United States equity market, and includes pharmaceutical companies such as manufacturers of prescription or over-the-counter drugs or vaccines, but excludes producers of vitamins.